Related Experiment Video

Updated: Aug 26, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.7K

Cell administration routes for heart failure: a comparative re-evaluation of the REGENERATE-DCM and REGENERATE-IHD

Doo Sun Sim1,2, Daniel A Jones1,3, Ceri Davies1,3

  • 1Centre for Cardiovascular Medicine & Devices, William Harvey Research Institute, Queen Mary University of London, London, UK.

Regenerative Medicine
|October 13, 2022
PubMed

Insights

Intracoronary cell delivery shows significant efficacy for heart failure patients, improving ejection fraction and quality of life. This simpler method offers a promising alternative to intramyocardial delivery in clinical trials.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Clinical Trials

Background:

  • Intramyocardial cell delivery faces logistical challenges for heart failure treatment.
  • Autologous cell therapy has shown potential in treating heart failure.

Purpose of the Study:

  • To evaluate the efficacy of the intracoronary cell delivery route.
  • To re-analyze data from REGENERATE-DCM and REGENERATE-IHD trials for heart failure.

Main Methods:

  • Retrospective statistical analysis of combined data from 150 patients.
  • Evaluation of endpoints including left ventricular ejection fraction (LVEF), NT-proBNP, NYHA class, and quality of life.

Main Results:

  • Intracoronary delivery demonstrated significant improvements in LVEF (3.7%), NT-proBNP (-76 pg/ml), NYHA class (48% patients), and quality of life.
  • Improvements in LVEF, NYHA class, and quality of life were statistically significant compared to the control group.

Conclusions:

  • Intracoronary cell delivery presents a viable and effective strategy for heart failure.
  • The logistical simplicity and demonstrated efficacy support its consideration in future clinical trials for heart failure.

Keywords:
adult stem cellscardiologycell therapyclinical trialheart failurerepairstem cells

More Related Videos

Intramyocardial Cell Delivery: Observations in Murine Hearts08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

13.6K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.0K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
488
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
686
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25